Results 71 to 80 of about 362,045 (252)

Plasma levels of remnant particles are determined in part by variation in the APOC3 gene insulin response element and the APOCI–APOE cluster

Journal of Lipid Research, 2000
Remnant particles of triglyceride-rich lipoproteins (RLP) are known to be a strong predictor of atherogenicity. The serum concentrations of remnant-like particle triglyceride (RLPTG) and remnant-like particle cholesterol (RLPC) have been determined in a ...
D.M. Waterworth, J.A. Hubacek, J. Pitha, J. Kovar, R. Poledne, S.E. Humphries, P.J. Talmud   +6 more
doaj   +1 more source

Additional file 1 of Longitudinal association of remnant cholesterol with joint arteriosclerosis and atherosclerosis progression beyond LDL cholesterol

, 2023
Additional file 1: Table S1. Baseline characteristics in male and female. Table S2. Diagnostic criteria for choosing the group number and shape parameter of the final multi-trajectory model. Table S3.
Zhiyuan Wu (114653), Zhiwei Li (131853), Xinlei Miao (11086052), Haiping Zhang (2644903), Xiuhua Guo (311454), Jinqi Wang (11086049), Ze Han (1484506), Wei Wang (17594), Yue Liu (292931), Xiaoping Kang (149234), Huiying Pan (11645463), Xia Li (14984), Lixin Tao (519670)   +12 more
core   +1 more source

Sertraline Treatment Can Mimic Niemann‐Pick Type C Biomarker Profile: A Diagnostic Pitfall

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Oxysterols (cholestane‐3β,5α,6β‐triol and 7‐ketocholesterol) and N‐palmitoyl‐O‐phosphocholineserine (PPCS) are sensitive biomarkers for Niemann‐Pick disease type C (NPC) screening. However, false‐positive results occur, with a biomarker profile suggestive of NPC despite the absence of pathogenic variants in genes involved in NPC or ...
Maria Makrygianni, Cecile Pagan, Antony Citterio‐Quentin, Isabelle Rouvet, Giulia Dingeo, Cyril Hanin, Claudine Laurent‐Levinson, Samia Pichard, Bénédicte Héron, Clément Gourguechon, Daniele Mandia, Jerome Guitton, Carole Lacout, Nicolas Schleinitz, Florient Potier, Olivier Flabeau, Elsa Besse‐Pinot, Foudil Lamari, Magali Pettazzoni, Yann Nadjar   +19 more
wiley   +1 more source

Effects of Add‐On Icosapent Ethyl With Standard Treatment on Functional Outcomes and Inflammatory Biomarkers in Acute Ischemic Stroke: A Blinded Randomized Controlled Trial

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand, Seyed Hossein Aghamiri, Saeed Mohmammad Soleymani, Shadiyeh Bararpoor Poshkohi, Samaneh Masoudi, Hadi Esmaily   +5 more
wiley   +1 more source

Remnant cholesterol, LDL cholesterol, and apoB absolute mass changes explain results of the PROMINENT trial

Background and aimsThe PROMINENT trial, a cardiovascular outcome trial of the triglyceride- and remnant cholesterol-lowering agent pemafibrate, has shown neutral results despite reduction in plasma triglycerides and remnant cholesterol.
Nordestgaard, Børge G., Langsted, Anne, Doi, Takahito   +2 more
core   +1 more source

Arterial retention of remnant lipoproteins ex-vivo is increased during insulin resistance due to increased arterial biglycan and production of cholesterol-rich atherogenic particles, that can be improved by ezetimibe in the JCR:LA-cp rat [PDF]

, 2012
Background Literature supports the “response-to-retention” hypothesis—that during insulin resistance, impaired metabolism of remnant lipoproteins can contribute to accelerated cardiovascular disease progression.
Uwiera, Richard R. E., Russell, James C., Cheeseman, Christopher I., Mangat, Rabban, Borthwick, Faye, Warnakula, Samantha, Hassanali, Zahra, Proctor, Spencer D., Vine, Donna F.   +8 more
core   +1 more source

Roles of remnant cholesterol in the risk factor, occurrence and in-hospital outcomes of stroke

, 2023
Background Stroke is the leading cause of death and disability with high incidence and recurrence rates and has caused severe social burden worldwide.
Wu, Zhiyuan
core   +1 more source

Diabetes‐Associated Cognitive Impairment: Pathophysiology and Emerging Therapies

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Diabetes‐associated cognitive impairment (DACI) is a common yet underrecognized condition, manifesting along a spectrum from mild cognitive impairment to dementia. DACI encompasses patients who develop vascular dementia (VaD) or Alzheimer's disease (AD) with diabetes as a risk factor; however, in certain patients, particularly those lacking ...
Osman Corbali, Priyanka Menon, Halil I. Corbali, Ram Jagannathan, Allan I. Levey   +4 more
wiley   +1 more source

Remnant cholesterol concentrations best explain the cardiovascular benefit of APOC3 genetic inhibition: a drug target Mendelian randomization study. [PDF]

AIMS: Apolipoprotein C-III (APOC3) inhibitors are approved for hypertriglyceridaemia. Genetic evidence suggests that APOC3 inhibition may also prevent coronary artery disease (CAD), but mechanisms remain unclear. METHODS AND RESULTS: To clarify how APOC3

core   +4 more sources

Vascular Disease, Non‐Steroidal Anti‐Inflammatory Drugs and Risk of Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives A history of vascular disease has been shown to be associated with an increased risk of Parkinson's disease, but this may be due to reverse causation. In addition, non‐steroidal anti‐inflammatory drugs are thought to reduce Parkinson's disease risk, but evidence is inconsistent and confounding by prior vascular disease is possible ...
Clare Wotton, Carol Hermon, Sarah Floud, Gillian Reeves, Isobel Barnes   +4 more
wiley   +1 more source